AI Drug Discovery for Pharma and Biotech

Drug discovery

74

papers

On emerging therapies

Overview

2-hydroxyglutaric aciduria encompasses three rare neurometabolic disorders (D-2, L-2, and combined D,L-2-hydroxyglutaric aciduria) caused by defects in mitochondrial enzymes or IDH2 mutations [1][3][14]. These autosomal recessive conditions (except D-2 type II, which is dominant) feature progressive cerebral damage, with symptoms including developmental delay, seizures, hypotonia, ataxia, and characteristic MRI findings (subcortical leukoencephalopathy in L-2-HGA; delayed cerebral maturation/ependymal cysts in D-2-HGA) [1][3][6][7]. Diagnosis relies on chiral urinary organic acid analysis and genetic testing [3][14].

Population

  • Each subtype affects <150 individuals globally, with combined D,L-2-HGA being the rarest (~12 cases) [3][12][18].

  • No sex or ethnic predilection is established for L-2-HGA/D-2-HGA [2][7].

Burden

  • L-2-HGA: Slow progression to severe disability by adulthood; 5% risk of cerebral neoplasms [9][11]

  • D-2-HGA: High mortality in neonatal-onset forms; cardiomyopathy in ~50% [3][4]

  • Combined D,L-2-HGA: Fatal in infancy/early childhood [12]

  • Caregiver economic/emotional burden is significant [19]

Therapies

  • No disease-modifying therapies exist. Management focuses on symptom control:

  • Antiseizure medications [3][14]

  • Physical/rehabilitation therapy for motor deficits [6][15]

  • Experimental approaches: IDH2 inhibitors (D-2-HGA type II), FAD/levocarnitine (L-2-HGA) [6][14]

Categories: rare genetic diseases, rare inborn errors of metabolism, rare neurological diseases

Research Papers

74 drug discovery papers about 2-hydroxyglutaric aciduria, with 1 first-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:

74 drug discovery papers about 2-hydroxyglutaric aciduria, with 1 first-in-class emerging drug candidate forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

small molecules
2026-04-28 | Metformin-NAD+ Precursor Combination for 2-HG Detoxification

Metformin activates AMPK-mediated enhancement of 2-hydroxyglutarate dehydrogenase expression while nicotinamide riboside supplementation provides cofactor support for the NAD+-dependent enzymatic clearance of accumulated 2-HG. This combination addresses both enzyme insufficiency and cofactor depletion in 2-hydroxyglutaric aciduria.

Open article ↗



2026-01-14 | Early manifestations of D-2-hydroxyglutaric aciduria type II

D-2-hydroxyglutaric aciduria type II (ICD-10 code E72.8: Other specified disorders of amino-acid metabolism, ОMIM #613657) is a rare neurometabolic disorder associated with a pathogenic mutation in the IDH2 gene, which encodes a mitochondrial enzyme called isocitrate dehydrogenase 2. The pathogenesis of the disease is based on the accumulation of neurotoxic and cytotoxic 2-hydroxyglutarate in the body fluids, leading to the development of characteristic clinical manifestations. These include neurological disorders and eye conditions, hypotonia, neurodevelopmental delay, seizures, and cardiomyopathy. D-2-hydroxyglutaric aciduria type II has not been sufficiently studied. Despite the introduction of many metabolic disorders in expanded newborn screening, including glutamic acidemias, which are similar in name and course, this disease is still diagnosed only with the help of special biochemical and molecular genetic tests. This article presents early manifestations, developmental characteristics, neuropsychological and infectious status in a child with D-2-hydroxyglutaric aciduria. Key words: D-2-hydroxyglutaric aciduria type II, D-2-hydroxyglutarate, IDH2 gene, epilepsy, cardiomyopathy, infectious process, developmental delay, hypoxic-ischemic encephalopathy, floppy infant syndrome

Open article ↗



2026-01-14 | 2-hydroxyglutaric aciduria in the practice of neonatologists and pediatricians: possibilities for early diagnosis and treatment

2-hydroxyglutaric aciduria (ICD-10 code E72.8: Other specified disorders of amino-acid metabolism) is a group of rare metabolic disorders resulting from the accumulation of α-ketoglutarate derivatives in mitochondria: D- and L-enantiomers of 2-hydroxyglutaric acid. This pathology is caused by a wide range of mutations in the genes of mitochondrial enzymes, which explains the existence of several subtypes of the disease in the described group. Over the 45 years since the first mention of 2-hydroxyglutaric aciduria, nearly 500 cases have been reported worldwide. 2-hydroxyglutaric aciduria leads to multisystemic disorders, primarily neurological, severe disability, or death, which determines the importance of early diagnosis. The disease is not included in neonatal screening, but certain similarities between its clinical and laboratory manifestations and various acidemias and other metabolic disorders, as well as their severe consequences and outcomes, necessitate further study and systematization of knowledge about this pathology. This article describes current approaches to the diagnosis and treatment of 2-hydroxyglutaric aciduria in newborns and young children. Key words: inherited metabolic disorders, aciduria, 2-hydroxyglutaric acid, 2-hydroxyglutaric aciduria, D-2-hydroxyglutaric aciduria types I and II, L-2-hydroxyglutaric aciduria

Open article ↗



2025-12-25 | Successful Treatment of 2-hydroxyglutaric Aciduria Diagnosed in Adulthood, Three Decades After the Onset: A Case Report and Literature Review.

2-Hydroxyglutaric aciduria is a rare genetic metabolic disorder, especially in Japan. Although magnetic resonance images show characteristic abnormalities in the subcortical white matter, some cases have been diagnosed in adulthood, namely many decades after onset. We herein report the case of a bedridden 37-year-old 2-hydroxyglutaric aciduria male patient who was diagnosed three decades after onset. Despite this, combination treatment with riboflavin and levocarnitine improved his condition, thus allowing him to walk by himself. Considering our case and the previous literature, we emphasize the importance of correctly diagnosing and treating patients with 2-hydroxyglutaric aciduria.

Open article ↗



2025-06-04 | L‐2‐Hydroxyglutaric Aciduria Complicated by Cerebral Neoplasm

Data S1. Investigations of index patient. MRI (magnetic resonance imaging) brain of the index patient at the age of 15 years. Genetic report of the index patient. Data S2. Summary and neuroimaging of the affected younger sibling. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Open article ↗



proteins
2026-09-01 | Metabolic Adaptation to Hypoxia in Epidermal Stem Cells: The Critical Role of L-2- Hydroxyglutarate Dehydrogenase in Skin Development

Stem cells are sustained within specialized niches where environmental cues, including oxygen availability, shape their ability to balance proliferation and differentiation. The epidermal stem cell (EpSC) niche is physiologically hypoxic, yet how EpSCs adapt to the metabolic consequences of low oxygen remains poorly understood. In this thesis, I identify the mitochondrial enzyme L-2-hydroxyglutarate dehydrogenase (L2HGDH) as a critical safeguard against the toxic accumulation of the hypoxia-induced metabolite L-2-hydroxyglutarate (L-2HG). Using genetic deletion and metabolite supplementation approaches, I demonstrate that L- 2HG accumulation impairs EpSC proliferation, prolongs the cell cycle, and induces DNA damage. These defects are exacerbated under hypoxia and partially rescued by over-expression of L2HGDH, establishing L-2HG as a key mediator of the hypoxic response. RNA sequencing of L2HGDH-deficient EpSCs revealed broad transcriptional suppression, particularly of genes involved in mitotic progression and DNA repair, consistent with the observed proliferation defects. While L-2HG can inhibit αKG-dependent dioxygenases, changes in histone methylation were modest, suggesting that other metabolic consequences of L2HGDH loss. Metabolomic profiling of L2HGDH deficient EpSCs uncovered broad metabolic alterations including reduced TCA cycle intermediates, and an increased SAM/SAH ratio, pointing to impaired mitochondrial function and change in methylation capacity. In addition, an increased redox species was observed, which might be underlying reason of DNA damage. Together, these findings reveal that L2HGDH is indispensable for preserving EpSC proliferation and genome integrity by preventing toxic L-2HG accumulation. More broadly, this work highlights how metabolic adaptation to hypoxia is essential for stem cell function and suggests that disruption of this pathway underlies the developmental and pathological features of L-2-hydroxyglutaric aciduria.

Open article ↗



small molecules
2026-04-28 | Metformin-NAD+ Precursor Combination for 2-HG Detoxification

Metformin activates AMPK-mediated enhancement of 2-hydroxyglutarate dehydrogenase expression while nicotinamide riboside supplementation provides cofactor support for the NAD+-dependent enzymatic clearance of accumulated 2-HG. This combination addresses both enzyme insufficiency and cofactor depletion in 2-hydroxyglutaric aciduria.

Open article ↗



2026-01-14 | Early manifestations of D-2-hydroxyglutaric aciduria type II

D-2-hydroxyglutaric aciduria type II (ICD-10 code E72.8: Other specified disorders of amino-acid metabolism, ОMIM #613657) is a rare neurometabolic disorder associated with a pathogenic mutation in the IDH2 gene, which encodes a mitochondrial enzyme called isocitrate dehydrogenase 2. The pathogenesis of the disease is based on the accumulation of neurotoxic and cytotoxic 2-hydroxyglutarate in the body fluids, leading to the development of characteristic clinical manifestations. These include neurological disorders and eye conditions, hypotonia, neurodevelopmental delay, seizures, and cardiomyopathy. D-2-hydroxyglutaric aciduria type II has not been sufficiently studied. Despite the introduction of many metabolic disorders in expanded newborn screening, including glutamic acidemias, which are similar in name and course, this disease is still diagnosed only with the help of special biochemical and molecular genetic tests. This article presents early manifestations, developmental characteristics, neuropsychological and infectious status in a child with D-2-hydroxyglutaric aciduria. Key words: D-2-hydroxyglutaric aciduria type II, D-2-hydroxyglutarate, IDH2 gene, epilepsy, cardiomyopathy, infectious process, developmental delay, hypoxic-ischemic encephalopathy, floppy infant syndrome

Open article ↗



2026-01-14 | 2-hydroxyglutaric aciduria in the practice of neonatologists and pediatricians: possibilities for early diagnosis and treatment

2-hydroxyglutaric aciduria (ICD-10 code E72.8: Other specified disorders of amino-acid metabolism) is a group of rare metabolic disorders resulting from the accumulation of α-ketoglutarate derivatives in mitochondria: D- and L-enantiomers of 2-hydroxyglutaric acid. This pathology is caused by a wide range of mutations in the genes of mitochondrial enzymes, which explains the existence of several subtypes of the disease in the described group. Over the 45 years since the first mention of 2-hydroxyglutaric aciduria, nearly 500 cases have been reported worldwide. 2-hydroxyglutaric aciduria leads to multisystemic disorders, primarily neurological, severe disability, or death, which determines the importance of early diagnosis. The disease is not included in neonatal screening, but certain similarities between its clinical and laboratory manifestations and various acidemias and other metabolic disorders, as well as their severe consequences and outcomes, necessitate further study and systematization of knowledge about this pathology. This article describes current approaches to the diagnosis and treatment of 2-hydroxyglutaric aciduria in newborns and young children. Key words: inherited metabolic disorders, aciduria, 2-hydroxyglutaric acid, 2-hydroxyglutaric aciduria, D-2-hydroxyglutaric aciduria types I and II, L-2-hydroxyglutaric aciduria

Open article ↗



2025-12-25 | Successful Treatment of 2-hydroxyglutaric Aciduria Diagnosed in Adulthood, Three Decades After the Onset: A Case Report and Literature Review.

2-Hydroxyglutaric aciduria is a rare genetic metabolic disorder, especially in Japan. Although magnetic resonance images show characteristic abnormalities in the subcortical white matter, some cases have been diagnosed in adulthood, namely many decades after onset. We herein report the case of a bedridden 37-year-old 2-hydroxyglutaric aciduria male patient who was diagnosed three decades after onset. Despite this, combination treatment with riboflavin and levocarnitine improved his condition, thus allowing him to walk by himself. Considering our case and the previous literature, we emphasize the importance of correctly diagnosing and treating patients with 2-hydroxyglutaric aciduria.

Open article ↗



2025-06-04 | L‐2‐Hydroxyglutaric Aciduria Complicated by Cerebral Neoplasm

Data S1. Investigations of index patient. MRI (magnetic resonance imaging) brain of the index patient at the age of 15 years. Genetic report of the index patient. Data S2. Summary and neuroimaging of the affected younger sibling. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Open article ↗



proteins
2026-09-01 | Metabolic Adaptation to Hypoxia in Epidermal Stem Cells: The Critical Role of L-2- Hydroxyglutarate Dehydrogenase in Skin Development

Stem cells are sustained within specialized niches where environmental cues, including oxygen availability, shape their ability to balance proliferation and differentiation. The epidermal stem cell (EpSC) niche is physiologically hypoxic, yet how EpSCs adapt to the metabolic consequences of low oxygen remains poorly understood. In this thesis, I identify the mitochondrial enzyme L-2-hydroxyglutarate dehydrogenase (L2HGDH) as a critical safeguard against the toxic accumulation of the hypoxia-induced metabolite L-2-hydroxyglutarate (L-2HG). Using genetic deletion and metabolite supplementation approaches, I demonstrate that L- 2HG accumulation impairs EpSC proliferation, prolongs the cell cycle, and induces DNA damage. These defects are exacerbated under hypoxia and partially rescued by over-expression of L2HGDH, establishing L-2HG as a key mediator of the hypoxic response. RNA sequencing of L2HGDH-deficient EpSCs revealed broad transcriptional suppression, particularly of genes involved in mitotic progression and DNA repair, consistent with the observed proliferation defects. While L-2HG can inhibit αKG-dependent dioxygenases, changes in histone methylation were modest, suggesting that other metabolic consequences of L2HGDH loss. Metabolomic profiling of L2HGDH deficient EpSCs uncovered broad metabolic alterations including reduced TCA cycle intermediates, and an increased SAM/SAH ratio, pointing to impaired mitochondrial function and change in methylation capacity. In addition, an increased redox species was observed, which might be underlying reason of DNA damage. Together, these findings reveal that L2HGDH is indispensable for preserving EpSC proliferation and genome integrity by preventing toxic L-2HG accumulation. More broadly, this work highlights how metabolic adaptation to hypoxia is essential for stem cell function and suggests that disruption of this pathway underlies the developmental and pathological features of L-2-hydroxyglutaric aciduria.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.